Treatment History of Youth At-Risk for Serious Mental Illness
Poster B90, Tuesday, October%209, 11:30%20am%20-%201:00%20pm, Essex%20Ballroom
Megan Farris1, Glenda MacQueen1, Benjamin Goldstein2,3, JianLi Wang4,5, Sidney Kennedy6,7,8,9,10, Signe Bray1,11,12, Catherine Lebel1,11,12, Jean Addington1; 1Hotchkiss Brain Institute, Department of Psychiatry, University of Calgary, Calgary, Alberta, Canada, 2Centre for Youth Bipolar Disorder, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada, 3Departments of Psychiatry and Pharmacology, Faculty of Medicine, University of Toronto, Toronto, Ontario Canada, 4Work & Mental health Research Unit, Institute of Mental Health Research, University of Ottawa, Ottawa, Ontario Canada, 5School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, Ottawa, Ontario Canada, 6Department of Psychiatry, University Health Network, Toronto, Ontario Canada, 7Department of Psychiatry, St. Michael's Hospital, Toronto, Ontario Canada, 8Arthur Sommer Rotenberg Chair in Suicide and Depression Studies, St. Michael's Hospital, Toronto, Ontario, Canada, 9Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, Ontario Canada, 10Krembil Research Institute, University Health Network, Toronto, Ontario Canada, 11Department of Radiology, University of Calgary, Calgary, Alberta Canada, 12Alberta Children's Hospital Research Institute & Child & Adolescent Imaging Research (CAIR) Program, Calgary, Alberta Canada
The aim was to describe the treatment history including medications, psychosocial therapy and hospital visits of participants in the Canadian Psychiatric Risk and Outcomes Study (PROCAN). PROCAN is a two-site study of 243 youth and young adults aged 12-25 years, categorized into four groups: healthy controls (n=42), stage 0 (non-help seeking, asymptomatic with risk mainly family history of serious mental illness (SMI); n=41), stage 1a (distress disorders; n=52) and stage 1b (attenuated syndromes; n=108). Participants were interviewed regarding lifetime and current treatments, including medications, psychosocial therapies and hospital visits. The number receiving baseline medications differed significantly across groups (p<0.001): 0% healthy controls, 14.6% stage 0, 32.7% stage 1a and 34.3% stage 1b. Further, 26.9% and 49.1% of stage 1a and stage 1b received psychosocial therapy at baseline, again indicative of statistically significant differences between groups (p<0.001). Similar results were observed for lifetime treatment history; as stage 1b participants had the highest frequency of lifetime treatment. Medications started in adulthood (>18 years of age) were the most common for initiation of treatment compared to childhood (0-12 years of age) and adolescence (>12-<18 years of age) for stage 1a and 1b participants. Lifetime mental health hospital visits differed significantly across groups (p<0.001) and were most common in stage 1b participants (29.6%) followed by stage 1a (13.5%), stage 0 (4.9%) and healthy controls (2.4%). We found that treatment history for participants in the PROCAN study differed between at-risk groups. Future initiatives focused on determining the effects of treatment history on SMI are warranted.
Topic Area: Ultra High Risk / Prodromal Research